RecruitingNot ApplicableNCT06492746

Personal BP - CAI Study

Assessing for Personalized Blood Pressure Targets During Cardiopulmonary Bypass With the Proprietary Cerebral Adaptive Index: A Pilot Investigation

Sponsor

Becton, Dickinson and Company

Enrollment

120 participants

Start Date

Jun 3, 2024

Study Type

INTERVENTIONAL

Conditions

Blood Pressure

Summary

A single-center, prospective, observational pilot of the Cerebral Adaptive Index for assessing personalized blood pressure targets

Eligibility

Min Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called HemoSphere Advanced Monitoring Platform with Acumen IQ sensor and Tissue Oximetry Monitoring for people with blood pressure. The study is currently recruiting participants at 1 location. People eligible for this study include aged 45 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEHemoSphere Advanced Monitoring Platform with Acumen IQ sensor and Tissue Oximetry Monitoring

The arterial line with Acumen IQ sensor and Foresight Elite sensor will be connected to the HemoSphere monitor with laptop displaying the CAI parameter.

Locations(1)

Northwestern University Hospital

Evanston, Illinois, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06492746

Related Trials

Accuracy of a Cuffless Photoplethysmography (PPG) Chest-Patch Monitor for 24-hour Ambulatory Blood Pressure Monitoring (ABPM)

NCT0724083111 locations

AI-Guided Predictions of Blood Pressure Dysregulation Using Perfusion Index as a Novel Biomarker in Persons With Spinal Cord Injury

NCT076990941 location